Alexion Pharmaceuticals

$159.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.87 (+1.18%) Today

-$0.36 (-0.23%) As of 11:49 AM UTC after-hours

Why Robinhood?

You can buy or sell ALXN and other stocks, options, and ETFs commission-free!

About ALXN

Alexion Pharmaceuticals, Inc. Common Stock, also called Alexion Pharmaceuticals, is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. The listed name for ALXN is Alexion Pharmaceuticals, Inc. Common Stock.

CEO

Ludwig N. Hantson

Employees

3,082

Headquarters

Boston, Massachusetts

Founded

1992

Market Cap

34.91B

Price-Earnings Ratio

37.33

Dividend Yield

—

Average Volume

3.74M

High Today

$160.33

Low Today

$158.01

Open Price

$158.35

Volume

2.79M

52 Week High

$160.33

52 Week Low

$72.67

Collections

Analyst Ratings

28%

of 18 ratings

Buy

28%

Hold

72%

Sell

ALXN Earnings

$0.00

$1.08

$2.16

$3.24

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 4, Pre-Market